In vitro formulation study demonstrates differential release profiles of telmisartan and hydrochlorothiazide in bilayer matrix tablets, suggesting viable fixed-dose combination therapy.
The aim of the presented work was formulation and in-vitro evaluation of bilayer tablets containing telmisartan as sustained release (SR) and hydrochlorothiazide as immediate release (IR) using HPMC. Tablets were evaluated via various quality control tests and in-vitro drug release studies. Drug release study was carried out hydrochloric acid buffer of pH 1.2 (0.1N) using USP paddle apparatus. The validated HPLC-UV method was applied to determine the amount of drugs released at different time intervals. Prepared tablets showed extended sustain release of telmisartan over a period of 20 h and hydrochlorothiazide as immediate release within 30 min.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: